$5.5 B

LOXO Mkt cap, 22-Jun-2018
Loxo Oncology Net income (Q1, 2018)-3.6 M
Loxo Oncology EBIT (Q1, 2018)-5.8 M
Loxo Oncology Cash, 31-Mar-2018103.8 M

Loxo Oncology Financials

Loxo Oncology Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

R&D expense

323 k14 m58.3 m

General and administrative expense

583 k10.5 m14.9 m

Operating expense total

906 k24.5 m73.2 m

Net Income

(10.3 m)(35.9 m)(72.4 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

2.8 m3.4 m8.4 m12.3 m14.2 m20.2 m24.4 m32 m

General and administrative expense

2.4 m2.6 m3.4 m3.8 m3.7 m4.8 m6.5 m12.2 m

Operating expense total

5.2 m5.9 m11.8 m16.1 m17.9 m24.9 m30.9 m44.2 m

EBIT

(5.8 m)

Interest income

2.2 m

Net Income

(8.1 m)(8.8 m)(11.6 m)(15.9 m)(17.7 m)(24.5 m)(30.4 m)(3.6 m)

Loxo Oncology Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016

Cash

43.9 m68.2 m30.4 m

Accounts Receivable

1.1 b

Current Assets

107.8 m156.6 m141.8 m

PP&E

12 k88 k248 k

Total Assets

114.5 m157.5 m145.3 m

Accounts Payable

239 k269 k1.1 m

Total Liabilities

15.1 m

Additional Paid-in Capital

143.7 m221.5 m269.4 m

Retained Earnings

(31 m)(66.8 m)(139.2 m)

Total Equity

112.7 m154.6 m130.2 m

Financial Leverage

1 x1 x1.1 x

Quarterly

USDQ1, 2017Q2, 2017Q1, 2018

Cash

48.5 m260.3 m103.8 m

Current Assets

244.4 m471.4 m720.6 m

PP&E

328 k364 k1.6 m

Total Assets

249.4 m472.4 m748.6 m

Accounts Payable

1.3 m2.2 m5.8 m

Current Liabilities

204.5 m

Total Liabilities

10.4 m11.2 m364.2 m

Additional Paid-in Capital

402.9 m655.6 m676.8 m

Retained Earnings

(163.8 m)(194.2 m)(291.7 m)

Total Equity

239 m461.3 m384.4 m

Financial Leverage

1 x1 x1.9 x

Loxo Oncology Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(20.7 m)(35.9 m)(72.4 m)

Depreciation and Amortization

1 k17 k77 k

Accounts Payable

18 k30 k792 k

Cash From Operating Activities

(2.8 m)(30.2 m)(51.3 m)

Purchases of PP&E

(14 k)(93 k)(237 k)

Cash From Investing Activities

(69.1 m)(17.2 m)(26.5 m)

Cash From Financing Activities

115.7 m71.6 m40 m

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(8.1 m)(8.8 m)(11.6 m)(15.9 m)(17.7 m)(24.5 m)(54.9 m)(3.6 m)

Depreciation and Amortization

21 k48 k80 k

Accounts Payable

207 k285 k415 k731 k758 k677 k1 m192 k1.1 m1.8 m

Cash From Operating Activities

(26.7 m)(50.5 m)109.8 m

Purchases of PP&E

(101 k)(164 k)(746 k)

Cash From Investing Activities

(84.7 m)(96.3 m)(148.2 m)

Cash From Financing Activities

129.5 m376.7 m229 k

Loxo Oncology Ratios

USDY, 2018

Financial Leverage

1.9 x
Report incorrect company information